Cellceutix Initiates Dose Escalation in Phase 2 Trial of Brilacidin for Ulcerative Proctitis

Cellceutix Initiates Dose Escalation in Phase 2 Trial of Brilacidin for Ulcerative Proctitis
Cellceutix has initiated the dose escalation of brilacidin (PMX-30063) in the second cohort of patients enrolled in a Phase 2 clinical trial evaluating the drug candidate for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS), two types of ulcerative colitis (UC). UP is a mucosal inflammatory bowel disease of unknown cause involving only the rectum.

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *